Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
1.
Pancreatology ; 24(3): 327-334, 2024 May.
Article in English | MEDLINE | ID: mdl-37880021

ABSTRACT

BACKGROUND: Acute pancreatitis (AP) is the most common gastrointestinal disease requiring hospitalization, with significant mortality and morbidity. We aimed to evaluate the clinical characteristics of AP and physicians' compliance with international guidelines during its management. METHODS: All patients with AP who were hospitalized at 17 tertiary centers in Turkey between April and October 2022 were evaluated in a prospective cohort study. Patients with insufficient data, COVID-19 and those aged below 18 years were excluded. The definitions were based on the 2012 revised Atlanta criteria. RESULTS: The study included 2144 patients (median age:58, 52 % female). The most common etiologies were biliary (n = 1438, 67.1 %), idiopathic (n = 259, 12 %), hypertriglyceridemia (n = 128, 6 %) and alcohol (n = 90, 4.2 %). Disease severity was mild in 1567 (73.1 %), moderate in 521 (24.3 %), and severe in 58 (2.6 %) patients. Morphology was necrotizing in 4.7 % of the patients. The overall mortality rate was 1.6 %. PASS and BISAP had the highest accuracy in predicting severe pancreatitis on admission (AUC:0.85 and 0.81, respectively). CT was performed in 61 % of the patients, with the majority (90 %) being within 72 h after admission. Prophylactic NSAIDs were not administered in 44 % of the patients with post-ERCP pancreatitis (n = 86). Antibiotics were administered to 53.7 % of the patients, and 38 % of those received them prophylactically. CONCLUSIONS: This prospective study provides an extensive report on clinical characteristics, management and outcomes of AP in real-world practice. Mortality remains high in severe cases and physicians' adherence to guidelines during management of the disease needs improvement in some aspects.


Subject(s)
Pancreatitis , Humans , Female , Aged , Male , Pancreatitis/etiology , Prospective Studies , Acute Disease , Turkey , Severity of Illness Index , Retrospective Studies
2.
Medicine (Baltimore) ; 101(36): e30488, 2022 Sep 09.
Article in English | MEDLINE | ID: mdl-36086763

ABSTRACT

Liver fibrosis is the most important factor in the prognosis and treatment plan of patients with chronic hepatitis B (CHB). Aspartate aminotransferase (AST)-to-platelet ratio index (APRI), fibrosis index based on 4 factors (FIB-4), and fibrosis index based on 5 factors (FIB-5) scores are noninvasive fibrosis markers, and previous comparative studies have shown that they are as effective as liver biopsy in detecting liver fibrosis in different liver diseases. The aim of our study is to investigate whether existing scoring systems are effective in demonstrating fibrosis in CHB patients and to compare the APRI, FIB 4, and FIB 5 scores in differentiating early and advanced fibrosis in 123 patients who underwent liver biopsy for CHB infection. APRI, FIB-4, and FIB-5 scores of patients who underwent liver biopsy due to CHB were calculated by means of calculators and recorded to be compared with liver biopsies in terms of fibrosis scoring. One hundred twenty-three patients who underwent liver biopsy due to chronic hepatitis B were included in the study. APRI (area under the receiver-operating characteristic [ROC] curve 0.728), FIB-4 (area under the ROC curve 0.693) and FIB-5 (area under the ROC curve 0.643) scores were evaluated as significant predictors of advanced fibrosis. The scoring system with the highest positive and negative predictive value was evaluated as FIB-4. APRI, FIB-4, and FIB-5 scoring systems are appropriate scoring systems in the assessment of advanced fibrosis in patients with CHB. Our study is the first to compare APRI, FIB-4, and FIB-5 values in CHB patients, and more comprehensive studies are needed.


Subject(s)
Hepatitis B, Chronic , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/pathology , Humans , Liver Cirrhosis/diagnosis , Liver Cirrhosis/pathology , Liver Function Tests , Platelet Count , Severity of Illness Index
3.
Turk J Gastroenterol ; 33(2): 111-118, 2022 02.
Article in English | MEDLINE | ID: mdl-35115294

ABSTRACT

BACKGROUND: There is limited data in the literature analyzing the efficacy of methotrexate in Crohn's disease used after thiopurine analogs. We aimed in our study to show the efficacy of methotrexate in Crohn's disease patients who failed to respond to thiopurine treatment. METHODS: The study included 29 azathioprine refractory patients with Crohn's disease. Intramuscular methotrexate (25 mg/week) in the induction of remission and intramuscular methotrexate (15 mg/week) in 29 CD patients with a median follow-up time of 13 months was performed. In 15 (51.7%) patients, methotrexate was used in combination with anti-Tumour necrosis factor (TNF) (combination group), while it was used in 14 (48.3%) patients in monotherapy (monotherapy group). RESULTS: The mean Harvey-Bradshaw index score significantly decreased in the follow-up period (Wk0 = 7.6, last visit = 4.5, P < .001). Remission and response rates at week 12 were 75.9% and 79.3%, respectively. Maintenance of remission (77.8% vs 37.5%, respectively, P = .1) and response rates (77.8% vs 50%, respectively, P = .3) due to last visit examination were numerically higher in combination group but they were not statistically significant. The cumulative probability of remission maintenance in patients with methotrexate therapy was 72.7%, 33.1%, and 22.0% at 1, 2 ,and 4 years after starting methotrexate, respectively. CONCLUSION: Our results show that parenteral use of methotrexate is efficacious in inducing and maintaining remission as a step-up agent in azathioprine refractory Crohn's disease patients.


Subject(s)
Azathioprine , Crohn Disease , Azathioprine/adverse effects , Crohn Disease/drug therapy , Humans , Immunosuppressive Agents/therapeutic use , Infliximab , Methotrexate/therapeutic use , Remission Induction , Treatment Outcome , Tumor Necrosis Factor-alpha
4.
Dig Dis ; 40(6): 728-733, 2022.
Article in English | MEDLINE | ID: mdl-35100590

ABSTRACT

BACKGROUND: The treatment of solitary rectal ulcer (SRU) is challenging and controversial; generally, no response to conventional treatments can be obtained, particularly in patients with dyssynergic defecation (DD). We assessed the efficiency of biofeedback therapy (BFT) in patients who did not respond to conservative treatments and had coexistence of SRU and DD. METHODS: BFT responses, as well as anorectal manometry and rectoscopy results of 20 patients with the coexistence of SRU and DD, were assessed. RESULTS: Mean age was 32.5 years. Of the patients, 12 were female, and 8 of them were male. An average of 12 sessions of BFT was performed on the patients. Ulcer disappeared in 11 patients (55%) after BFT, and the ulcer size decreased in 3 patients (15%). However, ulcers healed in 9 (90%) of 10 patients whose DD pattern disappeared following BFT, and ulcers healed in only 20% of patients whose DD pattern continued (p = 0.005). The change in anal resting pressure after BFT was significant (p = 0.016). Ulcers were healed in 87.5% (7/8) of the patients whose anal resting pressure decreased after BFT and whose DD disappeared, while ulcers remained untreated in 85.7% of the patients whose anal resting pressure decreased, but the DD pattern continued (p = 0.005). CONCLUSIONS: SRU patients with DD are typically unresponsive to medical treatments. Ameliorating anorectal dyssynergia should be the priority of treatment in these patients. BFT is an effective treatment for DD. BFT enhances the healing of ulcers in patients with SRU by restoring coordination of the pelvic floor.


Subject(s)
Defecation , Ulcer , Humans , Male , Female , Adult , Ulcer/therapy , Constipation/therapy , Manometry , Biofeedback, Psychology/methods , Anal Canal , Ataxia/therapy
5.
Turk J Gastroenterol ; 32(6): 488-492, 2021 06.
Article in English | MEDLINE | ID: mdl-34405814

ABSTRACT

The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic.


Subject(s)
COVID-19/immunology , Immunocompromised Host , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/immunology , COVID-19/diagnosis , COVID-19/therapy , COVID-19 Vaccines/immunology , Drug Administration Schedule , Humans , Inflammatory Bowel Diseases/complications , Prognosis , Risk Factors , Withholding Treatment
6.
Helicobacter ; 26(3): e12795, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33818871

ABSTRACT

BACKGROUND: The purpose of this study was to compare the clinical symptoms and pathological consequences of Helicobacter pylori (H. pylori) infection between children and adults and determine the levels of expression of FOX3P and IL-17A to examine the Th17/Treg balance. METHODS: Forty pediatric and 40 adult patients who were followed up at the Pediatric Gastroenterology and Internal Medicine Gastroenterology Departments were enrolled in the study. In our case-control study, gastric tissue specimens were evaluated using the updated Sydney system, and the number of cells expressing FOXP3/IL-17A (Treg and Th17 cell markers) was analyzed immunohistochemically. In addition, each case was evaluated using a clinical follow-up questionnaire. RESULTS: Clinical signs and symptoms of children and adults were similar. IL-17A and FOXP3 levels were significantly higher in children and adults with H. pylori (+) than in those without H. pylori (-) (p < .001). In patients with H. pylori (+), the mean FOXP3 level was significantly higher, whereas the mean IL-17A level was significantly lower in children than in adults (p < 0001 for both groups). In children with H. pylori (+), bacterial density was negatively correlated with IL-17A level and positively correlated with FOXP3 level. In adults with H. pylori (+), there was a statistically significant, highly positive correlation between bacterial density and levels of IL-17A and FOXP3. CONCLUSIONS: Treg cells are suggested to more predominant in children than in adults, IL-17A levels decrease as H. pylori bacterial density increases. In conclusion, immune responses incline toward Treg , which increases the susceptibility to persistent infections.


Subject(s)
Forkhead Transcription Factors/immunology , Helicobacter Infections , Interleukin-17/immunology , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology , Adult , Case-Control Studies , Child , Helicobacter Infections/immunology , Helicobacter pylori , Humans
9.
J Med Biochem ; 37(2): 155-162, 2018 Apr.
Article in English | MEDLINE | ID: mdl-30581352

ABSTRACT

BACKGROUND: We investigated the sensitivity of neutrophil to lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as well as a combination of NLR and PLR to predict endoscopic disease severity based on mucosal assessment in ulcerative colitis (UC). METHODS: The study group consisted 104 patients with active UC, 104 patients in remission, and 105 healthy individuals. Disease activity was described with Rachmilewitz endoscopic activity index (EAI). Curve analysis was used to determine the optimal cutoff values of NLR and PLR for obtaining remission. The patients with both PLR and NLR values higher than the cutoff values were coded as ¼high risk,« those with one parameter higher were coded as ¼moderate risk«, those with both parameters lower than the cutoff values were coded as ¼low-risk« patients. RESULTS: The mean NLR and PLR values in the endoscopically active disease group were higher than the others, with higher values in the endoscopic remission group compared with the control group (p<0.001). Rachmilewitz EAI in high-risk patients was significantly higher than that in others (p<0.001). In Cox regression analyses, moderate and high risk, high erythrocyte sedimentation rate and high EAI were found as independent predictors of endoscopic active disease. CONCLUSIONS: This is the first study that investigated the use of NLR and PLR combination to assess endoscopic disease severity in UC. Either high NLR or PLR levels can predict active endoscopic disease. However, the use of these parameters in combination is more accurate in evaluating mucosal disease and inflammation in UC.

10.
Turk J Gastroenterol ; 28(Suppl 1): S33-S37, 2017 12.
Article in English | MEDLINE | ID: mdl-29199165

ABSTRACT

Lifestyle modification has an important role in the treatment of gastroesophageal reflux disease (GERD). The development of GERD symptoms with various foods shows individual differences. Although there is not enough evidence that certain substances in a diet could lead to GERD symptoms, the literature suggests that there might be a relationship between reflux development and salt, salted foods, chocolate, fatty foods, and fizzy drinks. Because lying on the left side and raising the head of the bed in a supine position reduces the development of nocturnal reflux symptoms, the head should be elevated for patients with reflux symptoms at night, and the patient should lie on the left side. Smoking and obesity (especially abdominal) trigger GERD symptoms. Whereas excessive physical activity is a significant risk factor for the development of GERD, regular and mild-moderate physical activity has been shown to reduce the symptoms of reflux.


Subject(s)
Gastroesophageal Reflux/therapy , Life Style , Risk Reduction Behavior , Adult , Diet/methods , Exercise , Female , Gastroesophageal Reflux/etiology , Humans , Male , Middle Aged , Posture
11.
Turk J Gastroenterol ; 28(Suppl 1): S48-S52, 2017 12.
Article in English | MEDLINE | ID: mdl-29199168

ABSTRACT

Proton pump inhibitors (PPIs) are the most effective agents in the first-line and maintenance treatment of gastroesophageal reflux disease. As the grade of esophagitis increases, an increase is also observed in the level of endoscopic response to PPIs. In the first-line therapy of patients with severe esophagitis (Los Angeles (LA) Grade C-D), administration of a standard dose of PPIs bid has been reported to be more beneficial than PPIs qd. While any intermittant and low dose-continuous treatment can be chosen for the maintenance therapy of patients with non-erosive reflux disease or mild esophagitis (LA Grade A-B), continuous use of a standard dose of PPIs is preferred in the maintenance therapy of patients with severe esophagitis (LA Grade C-D). In patients who use PPIs for a long time, the drug must be stopped by gradually decreasing the dose.


Subject(s)
Gastroesophageal Reflux/drug therapy , Maintenance Chemotherapy/methods , Proton Pump Inhibitors/administration & dosage , Adult , Humans , Middle Aged
12.
Turk J Gastroenterol ; 28(Suppl 1): S53-S56, 2017 12.
Article in English | MEDLINE | ID: mdl-29199169

ABSTRACT

Gastroesophageal reflux disease (GERD) is frequently seen during pregnancy. In the medical treatment of pregnant women with GERD, alginic acid and sucralfate can be used. Calcium- and magnesium-based antacids can also be used, particularly for patients with preeclampsia. In particular, ranitidine -a histamine-2 receptor blocker- is preferred. In the case of non-responsiveness to the abovementioned treatments, proton pump inhibitors (PPIs), except omeprazole, can be given considering the benefit-harm ratio for the mother and fetus after the first trimester. In cases with GERD during the lactation period, drugs having minimum systemic absorption, such as sucralfate and alginic acid, are preferable but there is no data.


Subject(s)
Alginates/therapeutic use , Antacids/therapeutic use , Gastroesophageal Reflux/drug therapy , Lactation/drug effects , Pregnancy Complications/drug therapy , Sucralfate/therapeutic use , Female , Glucuronic Acid/therapeutic use , Hexuronic Acids/therapeutic use , Humans , Omeprazole/adverse effects , Pregnancy , Proton Pump Inhibitors/therapeutic use , Ranitidine/therapeutic use
13.
Dig Dis Sci ; 61(10): 2949-2955, 2016 10.
Article in English | MEDLINE | ID: mdl-27250981

ABSTRACT

BACKGROUND/AIM: The clinical significance of gastric xanthelasmas is unknown. We conducted a case-control study in order to evaluate whether gastric xanthelasma is an indicator of advanced atrophic gastritis and intestinal metaplasia. MATERIAL AND METHOD: The study was conducted among 1400 patients who underwent elective upper endoscopy. Patients with gastric xanthelasma and atrophy and/or intestinal metaplasia constituted the study group (n = 55). The control group involved patients with only atrophic gastritis and/or intestinal metaplasia (n = 50). Histopathologic findings of the groups including the distribution of atrophic gastritis and/or intestinal metaplasia, operative link on gastritis assessment score, operative link on gastritis intestinal metaplasia assessment (OLGIM) score, and presence of dysplasia and malignancy were compared. Subgroup analysis was performed in order to establish the relation between the characteristics (size, number, and localization) of xanthelasmas, atrophy, and intestinal metaplasia. RESULTS: Multifocal atrophic gastritis was significantly more common in patients with a gastric xanthelasma (41.8 vs. 26.0 %, p = 0.03). Patients with multiple xanthelasmas had a significantly higher rate of intestinal metaplasia (p = 0.02) and a higher OLGIM score (p = 0.02) compared to those with a single xanthelasma. Dysplasia was detected in 8 (14.5 %) patients with a xanthelasma and 4 (8.0 %) patients without a xanthelasma (p = 0.2). CONCLUSION: Gastric xanthelasma(s) is a warning endoscopic sign for the presence of multifocal atrophic gastritis and advanced intestinal metaplasia.


Subject(s)
Gastritis, Atrophic/pathology , Stomach/pathology , Xanthomatosis/pathology , Aged , Case-Control Studies , Female , Gastritis, Atrophic/complications , Gastroscopy , Helicobacter Infections/complications , Humans , Male , Metaplasia/complications , Middle Aged , Risk Factors , Stomach Diseases/complications , Stomach Diseases/pathology , Xanthomatosis/complications
14.
Wien Klin Wochenschr ; 128(9-10): 335-40, 2016 May.
Article in English | MEDLINE | ID: mdl-26932797

ABSTRACT

BACKGROUND AND AIM: The aim of this study was to evaluate the efficacy of bismuth-based quadruple regiment as a first-line treatment for Helicobacter pylori (H. pylori) eradication in patients with unexplained iron deficiency anemia (IDA). The serum hepcidin-25, iron, ferritin levels and total iron-binding capacity were evaluated at baseline and after H. pylori eradication in order to assess whether H. pylori eradication plays a role in IDA related to H. pylori infection. METHODS: The study included 80 patients with unexplained IDA and H. pylori infection. All patients received pantoprazole (40 mg b.i.d.), bismuth subcitrate (120 mg q.i.d.), tetracycline (500 mg q.i.d.) and metronidazole (500 mg t.i.d.) over 14 days as H. pylori eradication regimen. In all patients, blood samples were drawn at baseline and 1 month after eradication therapy. In all patients, serum hepcidin-25 levels were determined by using commercially available enzyme-linked immunosorbent assay kits. RESULTS: There was an improvement in hemoglobin, iron, total iron-binding capacity and ferritin values after H. pylori eradication in all subjects. Serum hepcidin-25 levels significantly decreased after H. pylori eradication (p < 0.001). CONCLUSION: Gastric H. pylori infection is a common cause of IDA of unknown origin in adult patients. Our results provide evidence indicating that hepcidin level decreases after successful H. pylori eradication with improvement in IDA.


Subject(s)
Anemia, Iron-Deficiency/epidemiology , Anemia, Iron-Deficiency/prevention & control , Bacterial Load/statistics & numerical data , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Hepcidins/blood , Adult , Anemia, Iron-Deficiency/diagnosis , Anti-Bacterial Agents/therapeutic use , Biomarkers/blood , Comorbidity , Female , Helicobacter Infections/diagnosis , Helicobacter pylori/drug effects , Helicobacter pylori/isolation & purification , Humans , Iron/blood , Male , Middle Aged , Prevalence , Prognosis , Risk Factors , Treatment Outcome , Turkey/epidemiology
15.
Wien Klin Wochenschr ; 128(9-10): 329-34, 2016 May.
Article in English | MEDLINE | ID: mdl-26637331

ABSTRACT

BACKGROUND: In several studies, different risk factors other than antibiotic resistance have been documented with Helicobacter pylori eradication failure. We aimed in this study to investigate the relationship of gastric density of H. pylori, the occurrence/degree of gastric atrophy, and intestinal metaplasia (IM) with success rate of H. pylori eradication. METHODS: Two hundred consecutive treatment naive patients who received bismuth containing standart quadruple treatment due to H. pylori infection documented by histopathological examination of two antral or two corpal biopsies entered this retrospective study. The updated Sydney system was used to grade the activity of gastritis, density of H. pylori colonization, atrophy, and IM. Stages III and IV of operative link for gastritis assessment (OLGA) or the operative link on gastric intestinal metaplasia assessment (OLGIM) stages was considered as severe gastritis. H. pylori eradication was determined via stool H. pylori antigen test performed 4 weeks after the end of therapy. RESULTS: The presence of gastric atrophy and IM was significantly higher in patients with eradication failure (p = 0.001 and 0.01, respectively). Severe gastritis (OLGA III-IV and OLGIM III-IV) rates were higher in eradication failure group. A multiple linear regression analysis showed that OLGA and OLGIM stages were to be independent risk factors for eradication failure (p = 0.03 and 0.01, respectively). CONCLUSION: Our results suggested that histopathologically severe gastritis may cause H. pylori eradication failure. In addition, we found that H. pylori density was not a risk factor for treatment failure in patients who receive quadruple treatment.


Subject(s)
Bacterial Load/statistics & numerical data , Gastritis/drug therapy , Gastritis/epidemiology , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Helicobacter pylori/isolation & purification , Adult , Female , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Humans , Incidence , Male , Retrospective Studies , Risk Factors , Severity of Illness Index , Treatment Outcome , Turkey/epidemiology
17.
Medicine (Baltimore) ; 94(47): e1889, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26632683

ABSTRACT

Interleukin 33 (IL-33) is a cytokine belonging to the IL-1 superfamily. Soluble ST2 (sST2) binds to IL-33 and by functioning as trap receptor inhibits signal sending to Th2 via transmembrane ST2. Because Th2-type cytokines play an important role in fibrosis, the aim of this study is to determine whether sST2 can be used as a marker of fibrosis in chronic hepatitis B (CHB) patients or not.The study included 19 healthy controls, 54 patients with CHB, and 14 patients with cirrhosis because of CHB. The aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on the 4 factors (FIB-4) scores also calculated, and correlations between liver biopsies, sST2 levels, and these scores were analyzed in CHB and cirrhosis patients.The sST2 levels in patients with CHB were significantly higher than those in the control group subjects (median: 1133 pg/mL vs 762.5 pg/mL, respectively [P = 0.035]). In CHB patients, the METAVIR fibrosis score (stages from 0 to 4) showed a moderate correlation with serum sST2 level (r = 0.396, P = 0.004) and a weak correlation with FIB-4 score (r = 0.359, P = 0.008), but no correlation with APRI score (r = 0.253, P = 0.06). The under the curve value of serum sST2 was 0.68, and its prediction of significant fibrosis (METAVIR score ≥2) in values >674 pg/mL had a sensitivity of 91.7% and specificity of 40% (P = 0.009). According to multiple logistic regression analysis, only METAVIR fibrosis stage was found to be an independent predictor of serum sST2 elevation in CHB patients (P = 0.04).The sST2 level can be used for differentiating significant fibrosis from mild fibrosis in CHB patients. However, the efficacy of this marker should be verified by larger studies in the future.


Subject(s)
Biomarkers/blood , Hepatitis B, Chronic/blood , Liver Cirrhosis/blood , Receptors, Cell Surface/blood , Adult , Aged , Female , Hepatitis B, Chronic/complications , Humans , Interleukin-1 Receptor-Like 1 Protein , Liver/pathology , Liver Cirrhosis/etiology , Male , Middle Aged , Predictive Value of Tests , Sensitivity and Specificity
19.
Turk J Gastroenterol ; 26(1): 25-30, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25698267

ABSTRACT

BACKGROUND/AIMS: We aimed to describe the clinical course of Ulcerative colitis (UC) and the factors that predict the need for total colectomy in Turkish patients with severe UC receiving regular follow up. MATERIALS AND METHODS: We analyzed the demographic and clinical characteristics of 612 patients with UC receiving regular follow up between 1994 and 2010 in a tertiary referral center in Ankara. RESULTS: Men accounted for 58% of patients (M:F ratio, 1.4:1), and the mean age at diagnosis was 37.9 years. Of these, 32% had distal colitis and 8.8% had further extension, and 39 patients (6.4%) had chronic active disease. Steroid dependency and steroid resistance rates were 7.5% and 17.2%, respectively. In multivariate analysis, steroid dependency (p=0.04), steroid resistance (p=0.002), further extension (p<0.001), presence of extensive disease (p=0.006), and chronic active disease (p<0.001) were independent predictors of the need for total colectomy. Patients with chronic active disease had lower total colectomy free survival (p<0.001). CONCLUSION: The predictors of total colectomy were comparable with those previously reported in the literature. However, we identified further extension in disease localization to predict the need for total colectomy.


Subject(s)
Colectomy/statistics & numerical data , Colitis, Ulcerative/surgery , Adolescent , Adult , Age of Onset , Aged , Aged, 80 and over , Chronic Disease , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/pathology , Disease Progression , Female , Follow-Up Studies , Humans , Male , Medical Records/statistics & numerical data , Middle Aged , Multivariate Analysis , Retrospective Studies , Severity of Illness Index , Steroids/therapeutic use , Tertiary Care Centers , Turkey , Young Adult
20.
Turk J Gastroenterol ; 26(1): 31-5, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25698268

ABSTRACT

BACKGROUND/AIMS: The aim of this study was to compare the utility of the revised Mayo risk model (rMRM) and Child-Pugh scores (CPSs) for predicting the prognosis of disease in patients with primary sclerosing cholangitis (PSC). MATERIALS AND METHODS: Patients were divided into 2 groups: Group I (37 patients; alive and not requiring liver transplantation) and Group II (8 patients; deceased or requiring liver transplantation). rMRM suggests the possible survival percentage over a 4-year period. Thus, rMRM scores and CPSs on the first visit were calculated from the data at the time of diagnosis for patients diagnosed with PSC <4 years ago. rMRM scores and CPSs of patients with >4 years of follow-up were calculated using data from the visit 4 years prior to their last follow-up. RESULTS: Bivariate analyses showed that need for liver transplantation/mortality was correlated with either first visit CPS (r=0.481, p=0.001) or rMRM (r=0.452, p=0.002). Analysis of the area under the curve showed that both models performed similarly in terms of predicting the need for liver transplantation/mortality (rMRM: 0.780; CPS: 0.762; p=0.8). There was a significant difference in Kaplan-Meier survival rates between Group I and Group II for both risk models (rMRM: p<0.001; CPS: p<0.001) when the decisive event was death or need for liver transplantation. CONCLUSION: Both rMRM and CPSs are useful in risk assessment of patients with PSC. The ability to predict prognosis is similar for both risk models.


Subject(s)
Cholangitis, Sclerosing/classification , Cholangitis, Sclerosing/surgery , Liver Transplantation , Models, Theoretical , Adolescent , Adult , Age of Onset , Aged , Area Under Curve , Cholangitis, Sclerosing/mortality , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Prognosis , Risk Assessment/methods , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...